Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viruses as anticancer drugs.

Stephen J Russell1, Kah-Whye Peng

  • 1Molecular Medicine Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. sjr@mayo.edu

Trends in Pharmacological Sciences
|June 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors.

Cancer research communications·2026
Same author

Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition.

Molecular therapy. Oncology·2026
Same author

Low-density lipoproteins in human serum competitively inhibit the binding and entry of vesicular stomatitis virus.

Molecular therapy. Advances·2026
Same author

Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12.

Cell reports. Medicine·2024
Same author

Smoldering oncolysis by foamy virus carrying CD19 as a CAR target escapes CAR T detection by genomic modification.

Molecular therapy. Oncology·2024

Oncolytic viruses are engineered to selectively destroy cancer cells. Overcoming antiviral immunity and studying their pharmacokinetics are key to developing these viruses as effective anticancer drugs.

Area of Science:

  • Oncology
  • Virology
  • Pharmacology

Background:

  • Oncolytic viruses are emerging as a promising class of anticancer therapeutics.
  • These viruses selectively replicate within tumor cells, leading to tumor destruction while sparing healthy tissues.
  • Their development as drugs necessitates rigorous safety and efficacy evaluations in human subjects.

Purpose of the Study:

  • To review the current concepts and strategies in the development of oncolytic viruses as anticancer drugs.
  • To highlight the importance of tumor-specific targeting mechanisms for enhanced safety.
  • To discuss the challenges and advancements in addressing antiviral immunity and enabling pharmacokinetic studies.

Main Methods:

  • Review of virus-engineering strategies for tumor specificity.

Related Experiment Videos

  • Discussion of immune-evasive delivery systems and immunosuppressive therapies.
  • Exploration of marker gene engineering for pharmacokinetic monitoring.

    • Main Results:

    • Virus engineering offers ingenious strategies to achieve neoplastic tissue specificity, crucial for safety.
    • Antiviral immunity presents a significant hurdle to clinical efficacy, being addressed by novel delivery and drug strategies.
    • Marker gene integration facilitates noninvasive pharmacokinetic monitoring, essential for drug development.

    Conclusions:

    • Oncolytic virus therapy holds significant potential for cancer treatment.
    • Further research into targeting mechanisms, safety, efficacy, and pharmacokinetic studies is vital for clinical success.
    • Accelerating the development and approval of oncolytic viruses requires robust clinical data on their behavior in patients.